▼ -19.97% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for ChromaDex in the last 3 months. The average price target is $7.67, with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a -19.97% upside from the last price of $9.58.
The current consensus among 3 investment analysts is to buy stock in ChromaDex. This Buy consensus rating has held steady for over two years.
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.